Ask about this productRelated genes to: PHF19 antibody
- Gene:
- PHF19 NIH gene
- Name:
- PHD finger protein 19
- Previous symbol:
- -
- Synonyms:
- DKFZP727G051, PCL3, MTF2L1, TDRD19B
- Chromosome:
- 9q33.2
- Locus Type:
- gene with protein product
- Date approved:
- 2004-01-05
- Date modifiied:
- 2018-11-16
Related products to: PHF19 antibody
Related articles to: PHF19 antibody
- PHF1 and PHF19 are key accessory components of polycomb repressive complex 2 (PRC2) which is responsible for trimethylation at histone H3 lysine 27, ultimately leading to gene repression. PHF1 and 19 are known for their methyl-lysine reader Tudor domains that recognize methylated lysine 36 on H3, and they have also been implicated as drivers of a range of cancers, including multiple myeloma. Here, we describe the first small-molecule antagonist of the Tudor domains of PHF1 and 19. We screened an internal library of ∼ 1 K compounds against the Tudor domains using a TR-FRET assay. Upon validation of a hit compound, we performed structure-activity relationship (SAR) studies to better understand the binding mode and improve the affinity of the compound for the PHF1 and 19 Tudor domains. One such compound, UNC7242, which binds PHF1 with a of 1.13 ± 0.04 μM and PHF19 with a of 0.64 ± 0.14 μM, emerged as a lead compound. UNC7242 clearly demonstrates the ligandability of these disease-relevant proteins and serves as a starting point for the future development of potent and selective PHF1 and 19 chemical probes. - Source: PubMed
Publication date: 2026/03/02
Amick Isabelle EJohnson Rebecca LLiu JiuyangBussey-Sutton Cameron RMancera-Ortiz Ikeer YNorris-Drouin Jacqueline LBoyd Shelton RCholensky Stephanie HSpangler Cathy JMcGinty Robert KStrahl Brian DKutateladze Tatiana GFrye Stephen VJames Lindsey I - Platelet-derived growth factor-BB (PDGF-BB) is a critical factor in maintaining pericyte function. Damage to pericytes has been shown to accelerate the progression of Alzheimer's disease (AD). This study aimed to investigate the role of PDGF-BB in the pathogenesis of AD. - Source: PubMed
Publication date: 2026/03/11
Yang HeyunZhou HongyingZhao KeyingShi LingLi YulanZhao QiongYa JinRongWu Chongmin - Multiple myeloma (MM) is characterized by kidney deficiency, phlegm, and blood stasis as core findings, specifically in Traditional Chinese Medicine (TCM), and the kidney-tonifying, phlegm-resolving, and blood stasis-removing (KPR) method is a fundamental therapeutic approach for MM in TCM. Western medicine primarily focuses on targeted immunotherapy or chemotherapy for MM treatment, whereas TCM characterizes MM through distinct pathological patterns that directly correspond to immune microenvironment dysregulation. Emerging evidence implicates the PHD finger protein 19 (PHF19)/enhancer of zeste homolog 2 (EZH2)/trimethylated histone H3 at lysine 27 (H3K27me3) epigenetic axis in immune microenvironment dysregulation and MM progression. Notably, TCM "blood stasis" correlates with hypoxia-induced immune gene silencing in MM bone marrow, and KPR (a clinically validated TCM decoction with 16 herbs) acts on this axis via its active components that regulate EZH2 and epigenetic function, merging TCM syndrome differentiation with modern epigenetics. We have designed a randomized controlled trial (RCT) to investigate the mechanism of action and safety of the KPR method in MM. - Source: PubMed
Publication date: 2026/03/05
Sun XiaoqiZhou YongmingWang YujueDai YouyaZhu WenweiChen Hailin - This research endeavors to thoroughly examine the expression patterns, clinical relevance, and possible regulatory networks of PHD finger protein 19 (PHF19) in pheochromocytoma and paraganglioma (PCPG). PHF19, known for its role in tumor biology, is being investigated as a potential prognostic biomarker and immunotherapy target in PCPG. - Source: PubMed
Publication date: 2026/01/15
Li DongbingLyu Guizhen - EZH2, a core component of PRC2 complex, silences global gene expression by tri-methylating histone H3K27. It remains an elusive question that EZH2 hyperexpression discords with its H3K27me3 activity of gene suppression in advanced prostate cancer. Here, we report a nascent RNA-dependent PHF19-YTHDC1 condensate capable of switching EZH2-mediated gene suppression to activation during prostate cancer progression. We found that the long isoform of PRC2 accessory subunit PHF19, PHF19L, was highly expressed in advanced prostate cancer that promoted the tumor progression and hormonal therapy resistance. Mechanistically, PHF19L was recruited to the mA modified nascent RNA through YTHDC1 and formed a liquid-like YTHDC1-PHF19L condensate that pulled the EZH2 away from chromatin, resulting in reduced H3K27me3 deposition and the activated expression of EZH2-repressed genes. Therefore, our study reveals a biomolecular condensate that modulates the switch from EZH2-mediated epigenetic gene silence to activation during the progression of prostate cancer. - Source: PubMed
Publication date: 2025/10/23
Yuan ShuaiMing Dao-JingHe JiapengLiu Meng-YangHe Shao-HuaWeng HongXi ShuZhang Jin-HuiShi Ming-HuiCui Jin-LongLi Lu-YaoZhang HaozheWang Dan-QiLi FeiGuo Meng-MengCai YiTang Shi-DiWang Shuang-YingWang Xing-HuanZeng Xian-TaoHu Hailiang